表紙
市場調査レポート

PharmaSphere:米国の医療政策の最新動向 - 医療保険改革法(ACA)による利害関係者に対する影響分析

PharmaSphere: US Healthcare Policy Update - Impact Analysis of the Affordable Care Act on Stakeholders

発行 GlobalData 商品コード 290453
出版日 ページ情報 英文 83 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
PharmaSphere:米国の医療政策の最新動向 - 医療保険改革法(ACA)による利害関係者に対する影響分析 PharmaSphere: US Healthcare Policy Update - Impact Analysis of the Affordable Care Act on Stakeholders
出版日: 2013年11月30日 ページ情報: 英文 83 Pages
概要

当レポートでは、米国の医療制度の現状について調査分析し、医療保険改革法(Affordable Care Act:ACA)に焦点を当てて、、ACAの規定のタイムライン、利害関係者(支払者、提供者、製薬会社など)に与える潜在的な影響について検証して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 産業の動向

  • 米国の医療制度における支出の高騰
  • バイオシミラー:支持派と反対派
  • FDA安全・イノベーション法(FDASIA)

第4章 米国の医療制度改革

  • 概要
  • 個別の義務規定
  • ACA実行のタイムライン

第5章 利害関係者の分析

  • ACAにおける保険の補償の予算の影響
  • 提供者
  • 支払者
  • 製薬メーカー

第6章 戦略的見通し:将来の方向性

  • Obamacare(オバマ政権による医療保険改革)
  • 医療保険計画
  • 製薬会社
  • 薬局

第7章 付録

図表

目次
Product Code: GDHC004PSR

GlobalData's "PharmaSphere: US Healthcare Policy Update - Impact Analysis of the Affordable Care Act on Stakeholders" report provides essential information and analysis on the Affordable Care Act (ACA). GlobalData provides an in-depth analysis of the most significant provisions of the Act, which is expected to alter the landscape of the US healthcare system considerably. The report discusses the timeline of the ACA's provisions as well as the potential impact of these provisions on various stakeholders in the US healthcare system including payers, providers, and pharmaceutical companies. Furthermore, the report analyzes current trends as various stakeholders position themselves to benefit from the ongoing healthcare reform in the US. The report also provides an outlook on what to expect with the full implementation of the provisions of the ACA.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each provision, strategy, and factor discussed, with the aim of providing you with the tools needed for making informed business decisions in a rapidly changing US healthcare system.

Highlights

Key Questions Answered

  • What provisions of the ACA are coming into effect on January 1, 2014?
  • What are the implications of the ACA on the payers, providers, pharmaceutical companies, and patients?
  • In which therapeutic areas are companies more likely to benefit from the ACA?
  • What is the forecast for prescription drug spending in the US through 2021?
  • How will pharmacies position themselves to reap the benefits of the ACA's provisions, particularly with the provisions coming into effect in January 2014?
  • Are there potential healthcare access issues due to the ACA's provisions?

About the Report

GlobalData's "PharmaSphere: US Healthcare Policy Update - Impact Analysis of the Affordable Care Act on Stakeholders report is an essential source of information and analysis on the ACA. GlobalData provides an in-depth analysis of the impact of the ACA on various stakeholders within the US healthcare system, including payers, providers, and pharmaceutical companies. The report discusses key provisions of the Act which are expected to significantly alter the shape of US healthcare. Furthermore, it provides valuable insight on emerging trends as well as potential strategies that are expected to be explored by stakeholders to enable them benefit from these provisions.

Reasons to buy

  • The report provides a timeline of the ACA provisions and the potential impact on various stakeholders in the US healthcare system including providers, payers, and pharmaceutical companies
  • The report discusses the dynamics of the US pharmaceutical industry including generics, biosimilars, and the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012
  • The report contains expert insights on the strategies being used by these stakeholders to ensure that they benefit significantly from the implementation of the ACA's provisions
  • The report includes an outlook on future trends that are expected in the US healthcare system due to impact of the ACA

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
  • 2.2. Upcoming Related Reports
  • 2.3. Recently Published Reports

3. Industry Dynamics

  • 3.1. Soaring Expenditures in the US Healthcare System
    • 3.1.1. US Healthcare Spending and Funding: Following the Healthcare Dollars
    • 3.1.2. Generics: A Cost-Effective Option
  • 3.2. Biosimilars: Proponents and Opponents
    • 3.2.1. State Legislative Tussles
  • 3.3. The Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012

4. US Healthcare Reform

  • 4.1. Overview
  • 4.2. The Individual Mandate Provision
    • 4.2.1. The US Supreme Court Ruling
  • 4.3. Affordable Care Act Implementation Timeline
    • 4.3.1. 2010: Provisions Primarily Targeted at Increasing Healthcare Coverage
    • 4.3.2. 2011: Additional Rebates for Pharma
    • 4.3.3. 2012: The Emergence of Accountable Care Organizations
    • 4.3.4. What's New in 2013?
    • 4.3.5. Beyond 2013 (2014-2018)

5. Stakeholders' Analysis

  • 5.1. Budgetary Impact of Insurance Coverage Provisions in the Affordable Care Act
  • 5.2. Providers
    • 5.2.1. Medicaid Expansion will increase Patient Volume
    • 5.2.2. Looming Healthcare Access Problems?
    • 5.2.3. Potential Increase in Quality of Healthcare Services
  • 5.3. Payers
    • 5.3.1. Increase in Member Volume by Insurance Exchanges
    • 5.3.2. New Taxes and Industry Fees on Health Insurance Payers
    • 5.3.3. Tiered-Provider Networks Continue to Be a Cost-Containment Strategy
  • 5.4. Pharmaceutical Manufacturers
    • 5.4.1. The Affordable Care Act: What's in it for Pharmaceutical Manufacturers?
    • 5.4.2. Prescription Drug Spending Will Grow to over $480 Billion by 2021

6. Strategic Outlook: The Way Forward

  • 6.1. Obamacare Will Get "Rolling" Evaluation
  • 6.2. Significant Shuttling Expected within Health Insurance Plans
  • 6.3. The Pie Gets Even Bigger for Pharmaceutical Companies
  • 6.4. Pharmacies Will Cash-in on Obamacare

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Research Methodology
    • 7.3.1. Coverage
    • 7.3.2. Secondary Research
    • 7.3.3. Expert Panel Validation
  • 7.4. About the Authors
    • 7.4.1. Analyst
    • 7.4.2. Director of Healthcare Industry Dynamics
    • 7.4.3. Global Director of Epidemiology and Health Policy
    • 7.4.4. Global Head of Healthcare
  • 7.5. About the Industry Dynamics Team
  • 7.6. About GlobalData
  • 7.7. Disclosure Information
  • 7.8. Disclaimer

List of Tables

  • Table 1: Federal Medical Assistance Percentage for States with Newly Enrolled Medicaid Members
  • Table 2: Provisions of the Affordable Care Act Implemented in 2010
  • Table 3: Provisions of the Affordable Care Act Implemented in 2011
  • Table 4: Provisions of the Affordable Care Act Implemented in 2012
  • Table 5: Provisions of the Affordable Care Act Implemented in 2013
  • Table 6: Provisions of the Affordable Care Act to be Implemented in 2014-2018
  • Table 7: Estimate of Budgetary Effects of Coverage Provisions in the Affordable Care Act
  • Table 8: Annual Fees to be Generated from Health Insurance Providers from 2014
  • Table 9: Planned Reduction in Medicare Part D Coinsurance Rate for Branded and Generic Drugs, 2013-2020
  • Table 10: Annual Fees to Be Generated from Branded Drug Companies, 2012-2019

List of Figures

  • Figure 1: US Healthcare Expenditures and GDP, 2003-2012
  • Figure 2: US Per Capita Healthcare Expenditures and GDP, 2003-2012
  • Figure 3: US Personal Healthcare Spending by Service/Product, 2012
  • Figure 4: US Personal Healthcare Spending by Service/Product,1 2013-2021
  • Figure 5: US Healthcare Spending by Source of Funding,1 2012
  • Figure 6: US Healthcare Spending by Source of Funding,1 2010-2012
  • Figure 7: State Positions on Medicaid Expansion1
  • Figure 8: Timeline of Affordable Care Act Provisions Impacting Providers
  • Figure 9: Timeline of Affordable Care Act Provisions Impacting Payers
  • Figure 10: Domestic Exports of Pharmaceutical Products from the US, 1996-2011
  • Figure 11: Timeline of Affordable Care Act Provisions Impacting Pharmaceutical Companies
  • Figure 12: US Expenditures (Historical and Forecast) on Medicinal Products,1 2011-2021
  • Figure 13: Prescription Drug Expenditures,1 2011-2021
  • Figure 14: Prescription Drug Expenditures in the US (with and without the Affordable Care Act), 2011-2021
Back to Top